OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 15:27 UTC. Every row links to its source record.

OLIG2 oligodendrocyte transcription factor 2

ENSG00000205927 · protein coding · Open Targets profile

Required for oligodendrocyte and motor neuron specification in the spinal cord, as well as for the development of somatic motor neurons in the hindbrain. Works in coordination with ZNF488 to promote oligodendrocyte differentiation. Orchestrates progenitor cell fates during cortical gliogenesis and gliomagenesis. In cooperation with OLIG2, activates oligodendrocyte precursor cells (OPCs) formation while repressing the generation of olfactory bulb interneuron intermediate progenitors (OBIN) generation through transcriptional regulation of GSX2. Mechanistically, binds and silences multiple conserved enhancer elements of GSX2. Cooperates with OLIG1 to establish the pMN domain of the embryonic neural tube. Antagonist of V2 interneuron and of NKX2-2- induced V3 interneuron development. .

In 15 of 15 cancers, the evidence for OLIG2 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751colon adenocarcinomacolon adenocarcinomacolon adenocarcinoma: somatic 0.61endometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinoma: somatic 0.61colorectal adenocarcinomacolorectal adenocarcinomacolorectal adenocarcinoma: somatic 0.61breast carcinomabreast carcinomabreast carcinoma: somatic 0.46small cell lung carcinomasmall cell lung carcinomasmall cell lung carcinoma: somatic 0.46gastric intestinal type adenocarcinomagastric intestinal type adenocarcinomagastric intestinal type adenocarcinoma: somatic 0.46squamous cell lung carcinomasquamous cell lung carcinomasquamous cell lung carcinoma: somatic 0.46hepatobiliary neoplasmhepatobiliary neoplasmhepatobiliary neoplasm: somatic 0.46ovarian endometrioid adenocarcinoma wit…ovarian endometrioid adenocarcinoma with squamous differentiationovarian endometrioid adenocarcinoma with squamous differentiation: somatic 0.46hepatocellular carcinomahepatocellular carcinomahepatocellular carcinoma: somatic 0.46rectum adenocarcinomarectum adenocarcinomarectum adenocarcinoma: somatic 0.46skin basal cell carcinomaskin basal cell carcinomaskin basal cell carcinoma: somatic 0.46gastric carcinomagastric carcinomagastric carcinoma: somatic 0.46esophageal adenocarcinomaesophageal adenocarcinomaesophageal adenocarcinoma: somatic 0.46gastric adenocarcinomagastric adenocarcinomagastric adenocarcinoma: somatic 0.46

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

No positive tractability buckets.

gnomAD loss of function constraint: o/e 0.8983299732208252 (upper bound 1.4555000066757202). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of OLIG2's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of OLIG2's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.